The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Kazuo Tsubota - One of the best experts on this subject based on the ideXlab platform.

  • the effects of 3 Diquafosol sodium eye drops on tear function and the ocular surface of cu zn superoxide dismutase 1 sod1 knockout mice treated with antiglaucoma eye medications
    Diagnostics (Basel Switzerland), 2020
    Co-Authors: Yukari Yagiyaguchi, Kazuo Tsubota, Takashi Kojima, Murat Dogru, Osama M A Ibrahim, Kazunari Higa, Takahiko Shimizu, Jun Shimazaki
    Abstract:

    Anti-glaucoma eye drop treatment often induces dry eyes and can lead to poor medication adherence. This study aimed to investigate the effects of 3% Diquafosol sodium eye drops on tear function and the ocular surface epithelium in Sod1−/− mice after treatment with anti-glaucoma eye drops. The mice were divided into four groups: group 1, control group; group 2, anti-glaucoma eye drop; group 3, anti-glaucoma eye drops followed by a secretagogue eye drop (3% Diquafosol); and group 4, simultaneous anti-glaucoma and secretagogue eye drop. Mice underwent assessments of tear quantity, tear film breakup time, and vital staining score. Mice in groups 3 and 4 showed significantly better tear stability and lower corneal staining scores than mice in group 2 after eye drop instillations (p < 0.05). Mice in group 4 showed significantly better tear stability, lower corneal staining scores, and higher goblet cell densities than those in group 1 after eye drop instillations (p < 0.05). The conjunctival epithelium showed stratification and abundance of Muc5AC-positive goblet cells in group 4, whereas thinning with desquamation was observed with a few goblet cells in group 2. Thus, simultaneous administration of 3% Diquafosol sodium eye drops with topical anti-glaucoma drops showed favorable effects on tear stability and the corneal epithelium against the ocular surface toxicity inflicted by the anti-glaucoma eye drops.

  • The effects of 3% Diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
    Co-Authors: Keisuke Ikeda, Kazuo Tsubota, Takashi Kojima, Murat Dogru, Kazunari Higa, Takahiko Shimizu, Cem Simsek, Motoko Kawashima, Jun Shimazaki
    Abstract:

    Purpose The purpose of the study is to investigate the effect of 3% Diquafosol sodium eye drops on meibomian gland and ocular surface alterations in the superoxide dismutase-1 ( Sod1 ^ −/− ) mice in comparison to the wild-type mouse. Methods Three percent Diquafosol sodium eye drop was instilled to 20 eyes of 10 50-week-old male Sod1 ^ −/− mice and 22 eyes of 11 C57BL/6 strain 50-week-old wild-type (WT) male mice six times a day for 2 weeks. Aqueous tear secretion quantity was measured with phenol red-impregnated cotton threads without anesthesia. Tear film stability and corneal epithelial damage were assessed by fluorescein and lissamine green staining. We also performed oil red O (ORO) lipid staining to evaluate the lipid changes in the meibomian glands. Meibomian gland specimens underwent hematoxylin and eosin staining to examine histopathological changes and meibomian gland acinar unit density after sacrifice. Immunohistochemistry staining was performed using cytokeratin 4, cytokeratin 13, and transglutaminase-1 antibodies. Quantitative real-time polymerase chain reaction for cytokeratin 4, cytokeratin 13, and transglutaminase-1 mRNA expression was also performed. Results The aqueous tear quantity, the mean tear film breakup time, and the number of lipid droplets significantly improved in the Sod1 ^ −/− mice with treatment. The mean meibomian acinar unit density did not change in the Sod1 ^ −/− mice and WT mice after treatment. Application of 3% Diquafosol sodium eye drop significantly decreased the corneal fluorescein and lissamine green staining scores in the Sod1 ^ −/− mice after 2 weeks. We showed a notable increase in cytokeratin 4, cytokeratin 13 immunohistochemistry staining, and cytokeratin 4, cytokeratin 13 mRNA expressions with a marked decrease in immunohistochemistry staining and significant decline in mRNA expression of transglutaminase-1 after 3% Diquafosol sodium treatment. Conclusion Topical application of 3% Diquafosol sodium eye drop improved the number of lipid droplets, tear stability, and tear production which in turn appeared to have a favorable effect on the ocular surface epithelium. Three percent Diquafosol sodium eye drop may be a potential treatment for age-related meibomian gland and dry eye disease based on the observations of the current study.

  • the effects of 3 Diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the cu zn superoxide dismutase 1 sod1 knockout mice
    Graefes Archive for Clinical and Experimental Ophthalmology, 2018
    Co-Authors: Takashi Kojima, Murat Dogru, Kazunari Higa, Takahiko Shimizu, Keisuke Ikeda, Cem Simsek, Motoko Kawashima, Kazuo Tsubota
    Abstract:

    The purpose of the study is to investigate the effect of 3% Diquafosol sodium eye drops on meibomian gland and ocular surface alterations in the superoxide dismutase-1 (Sod1 −/− ) mice in comparison to the wild-type mouse. Three percent Diquafosol sodium eye drop was instilled to 20 eyes of 10 50-week-old male Sod1 −/− mice and 22 eyes of 11 C57BL/6 strain 50-week-old wild-type (WT) male mice six times a day for 2 weeks. Aqueous tear secretion quantity was measured with phenol red-impregnated cotton threads without anesthesia. Tear film stability and corneal epithelial damage were assessed by fluorescein and lissamine green staining. We also performed oil red O (ORO) lipid staining to evaluate the lipid changes in the meibomian glands. Meibomian gland specimens underwent hematoxylin and eosin staining to examine histopathological changes and meibomian gland acinar unit density after sacrifice. Immunohistochemistry staining was performed using cytokeratin 4, cytokeratin 13, and transglutaminase-1 antibodies. Quantitative real-time polymerase chain reaction for cytokeratin 4, cytokeratin 13, and transglutaminase-1 mRNA expression was also performed. The aqueous tear quantity, the mean tear film breakup time, and the number of lipid droplets significantly improved in the Sod1 −/− mice with treatment. The mean meibomian acinar unit density did not change in the Sod1 −/− mice and WT mice after treatment. Application of 3% Diquafosol sodium eye drop significantly decreased the corneal fluorescein and lissamine green staining scores in the Sod1 −/− mice after 2 weeks. We showed a notable increase in cytokeratin 4, cytokeratin 13 immunohistochemistry staining, and cytokeratin 4, cytokeratin 13 mRNA expressions with a marked decrease in immunohistochemistry staining and significant decline in mRNA expression of transglutaminase-1 after 3% Diquafosol sodium treatment. Topical application of 3% Diquafosol sodium eye drop improved the number of lipid droplets, tear stability, and tear production which in turn appeared to have a favorable effect on the ocular surface epithelium. Three percent Diquafosol sodium eye drop may be a potential treatment for age-related meibomian gland and dry eye disease based on the observations of the current study.

  • Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition
    Japanese Journal of Ophthalmology, 2015
    Co-Authors: Chika Shigeyasu, Masakazu Yamada, Yoko Akune, Kazuo Tsubota
    Abstract:

    Purpose To evaluate the clinical efficacy of 3 % Diquafosol sodium ophthalmic solution for dry eye, and to analyze the concentration of tear proteins and mucin-like substances after the treatment. Methods Fifty eyes of 25 patients with dry eye syndrome were prospectively enrolled. The patients were treated with Diquafosol solution at a dose of 1 drop in each eye 6 times daily for 4 weeks. The parameters of clinical efficacy were tear osmolarity, tear breakup time (BUT), fluorescein staining scores for the cornea and conjunctiva, Schirmer test values, and subjective symptoms evaluated using the ocular surface disease index (OSDI). Tears collected with Schirmer test strips were analyzed by high-performance liquid chromatography, and the concentrations of the total protein and the 4 major tear proteins, namely, secretory IgA, lactoferrin, lipocalin-1, lysozyme, and N-acetyl-neuraminic acid (Neu5Ac), were measured. Neu5Ac is a major sialic acid, a marker of secretory mucins. Results The BUT, keratoconjunctival staining scores, and Schirmer test values were improved with statistical significance after the treatment with Diquafosol solution, while changes in the other parameters, including tear osmolarity, corneal staining scores, and OSDI scores were not significant. The Neu5Ac concentration was significantly increased, which was not accompanied by changes in tear proteins. Conclusions Topical application of Diquafosol significantly improved the clinical parameters of the BUT, keratoconjunctival staining scores, and Schirmer test values and was accompanied by increased sialic acid content in the tears of patients with dry eye.

  • Diquafosol sodium ophthalmic solution for the treatment of dry eye clinical evaluation and biochemical analysis of tear composition
    Japanese Journal of Ophthalmology, 2015
    Co-Authors: Masakazu Yamada, Chika Shigeyasu, Yoko Akune, Kazuo Tsubota
    Abstract:

    Purpose To evaluate the clinical efficacy of 3 % Diquafosol sodium ophthalmic solution for dry eye, and to analyze the concentration of tear proteins and mucin-like substances after the treatment.

Hitoshi Watanabe - One of the best experts on this subject based on the ideXlab platform.

  • long term safety and effectiveness of Diquafosol for the treatment of dry eye in a real world setting a prospective observational study
    Advances in Therapy, 2020
    Co-Authors: Yuichi Ohashi, Hitoshi Watanabe, Etsuko Takamura, Norihiko Yokoi, Jun Shimazaki, Masahiro Munesue, Akio Nomura, Fumiki Shimada
    Abstract:

    Diquafosol is a P2Y2 receptor agonist that has been shown to be effective in the treatment of dry eye disease (DED) in short-term studies; however, its long-term safety and effectiveness have not been evaluated in a real-world setting. This prospective, multicentre, open-label observational study was conducted in patients with DED over 12 months. Safety endpoints included the incidence of adverse drug reactions (ADRs) and serious ADRs. Effectiveness endpoints included change from baseline in keratoconjunctival staining score, tear film break-up time (BUT) and Dry Eye-related Quality of Life Score (DEQS). A total of 580 patients were included, most of whom were female (82.9%). The proportion of patients who completed 12 months of observation was 55.0%, the most common reason for discontinuation was patient decision (54.6%). The incidence of ADRs was 10.7% and was highest during the first month of treatment (5.5%); no serious ADRs were reported. Compared with baseline, significant improvements in all effectiveness outcomes, including keratoconjunctival fluorescein staining score, BUT and DEQS summary score, were observed at each evaluation during the treatment period (p < 0.001). The present, real-world study showed that Diquafosol 3.0% ophthalmic solution was well tolerated and effective in the long-term treatment of DED.

  • Diquafosol ophthalmic solution increases pre and postlens tear film during contact lens wear in rabbit eyes
    Eye & Contact Lens-science and Clinical Practice, 2017
    Co-Authors: Yukiko Nagahara, Kohji Nishida, Yoshihiro Oshita, Takashi Nagano, Hidetoshi Mano, Hitoshi Watanabe
    Abstract:

    OBJECTIVES: To investigate the behavior of prelens tear film (PLTF) and postlens tear film (PoLTF) after the instillation of Diquafosol using an experimental rabbit model of eyes with contact lens. METHODS: Cross-sectional, anterior segment optical coherence tomographic images of the inferior midperipheral cornea were obtained at baseline and at 5, 15, 30, 60, 90, and 120 min after the instillation of 3% Diquafosol ophthalmic solution in 10 Japanese white rabbits wearing contact lenses. From the obtained images, the areas of the PLTF and PoLTF were calculated. Both artificial tear solution and 0.1% sodium hyaluronate ophthalmic solution were used for comparison. RESULTS: Significant fluid accumulation in both the PLTF and PoLTF was observed after Diquafosol instillation, whereas no fluid accumulation was visible after the instillation of artificial tear or sodium hyaluronate. The increase in PLTF area after Diquafosol instillation was significantly higher (P<0.01) at 15 and 30 min than that after the instillation of artificial tear or sodium hyaluronate. The increase in PoLTF area up to 60 min after the instillation of Diquafosol was significantly higher (P<0.01) than that after the instillation of either of the other two drugs. CONCLUSIONS: Instillation of 3% Diquafosol ophthalmic solution increases PLTF and PoLTF in rabbit eyes with contact lenses. Diquafosol has potential as a treatment option for contact lens-related dry eye.

  • Diquafosol Ophthalmic Solution Increases Pre- and Postlens Tear Film During Contact Lens Wear in Rabbit Eyes
    Eye & Contact Lens-science and Clinical Practice, 2017
    Co-Authors: Yukiko Nagahara, Kohji Nishida, Yoshihiro Oshita, Takashi Nagano, Hidetoshi Mano, Hitoshi Watanabe
    Abstract:

    To investigate the behavior of prelens tear film (PLTF) and postlens tear film (PoLTF) after the instillation of Diquafosol using an experimental rabbit model of eyes with contact lens. Cross-sectional, anterior segment optical coherence tomographic images of the inferior midperipheral cornea were obtained at baseline and at 5, 15, 30, 60, 90, and 120 min after the instillation of 3% Diquafosol ophthalmic solution in 10 Japanese white rabbits wearing contact lenses. From the obtained images, the areas of the PLTF and PoLTF were calculated. Both artificial tear solution and 0.1% sodium hyaluronate ophthalmic solution were used for comparison. Significant fluid accumulation in both the PLTF and PoLTF was observed after Diquafosol instillation, whereas no fluid accumulation was visible after the instillation of artificial tear or sodium hyaluronate. The increase in PLTF area after Diquafosol instillation was significantly higher (P

  • real world assessment of Diquafosol in dry eye patients with risk factors such as contact lens meibomian gland dysfunction and conjunctivochalasis subgroup analysis from a prospective observational study
    Clinical Ophthalmology, 2015
    Co-Authors: Masahiko Yamaguchi, Hitoshi Watanabe, Etsuko Takamura, Norihiko Yokoi, Takeshi Nishijima, Jun Shimazaki, Yuichi Ohashi
    Abstract:

    Purpose To evaluate the efficacy and safety of Diquafosol (DQS) ophthalmic solution in dry eye (DE) patients wearing contact lenses (CLs) or with concomitant meibomian gland dysfunction (MGD) or conjunctivochalasis in a real-world setting.

  • prolonged increase in tear meniscus height by 3 Diquafosol ophthalmic solution in eyes with contact lenses
    Clinical Ophthalmology, 2015
    Co-Authors: Yukiko Nagahara, Kohji Nishida, Hitoshi Watanabe
    Abstract:

    Purpose This study aimed to evaluate the increase in tear meniscus height (TMH) induced by 3% Diquafosol ophthalmic solution in eyes with contact lens (CL).

Kyung-chul Yoon - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
    Korean Journal of Ophthalmology, 2019
    Co-Authors: Chang-hyun Park, Jongsuk Song, Kyung-chul Yoon
    Abstract:

    Purpose To evaluate the efficacy and safety of cyclosporine nanoemulsion 0.05% compared to cyclosporine emulsion 0.05% and Diquafosol sodium 3%.

  • efficacy of topical cyclosporine nanoemulsion 0 05 compared with topical cyclosporine emulsion 0 05 and Diquafosol 3 in dry eye
    Korean Journal of Ophthalmology, 2019
    Co-Authors: Chang-hyun Park, Jongsuk Song, Kyung-chul Yoon, Tae Young Chung, Chul Young Choi
    Abstract:

    PURPOSE: To evaluate the efficacy and safety of cyclosporine nanoemulsion 0.05% compared to cyclosporine emulsion 0.05% and Diquafosol sodium 3%. METHODS: This was a multicenter, randomized, evaluator-masked, active control, parallel, phase IV study. A total of 227 patients were randomly allocated to instill cyclosporine nanoemulsion 0.05% (CN) twice daily, cyclosporine emulsion 0.05% (CE) twice daily, or Diquafosol sodium 3% (DQ) six times daily. Non-inferiority of CN was analyzed by primary endpoint (cornea and conjunctival staining scores at week 12). The secondary endpoints were scores of corneal staining, conjunctival staining, tear break-up time, Schirmer test, and Ocular Surface Disease Index at weeks 4 and 12. RESULTS: Primary endpoints showed statistically significant improvements in all groups. Primary endpoints were -6.60 for the CN group, -5.28 for the CE group, and -6.63 for the DQ group (National Eye Institute scale from 0 to 33), verifying the non-inferiority of CN compared to CE (95% confidence interval, -0.15 to 2.80, Δ>-2.88). In intergroup comparison between CN and CE groups, the CN group had significantly more decreased conjunctival staining score at week 12. Intergroup comparison between CN and DQ groups showed consistent statistically significant improvements in TBUT and Schirmer test in the CN group. In the DQ group, TBUT showed late statistically significant improvement at week 12 and Schirmer test showed relatively short-term statistically significant improvement at week 4. CONCLUSIONS: Cyclosporine nanoemulsion 0.05% was equivalently efficient compared to cyclosporine emulsion 0.05% and Diquafosol sodium 3%. In addition, CN showed significant improvements in several parameters for treatment of dry eyes.

  • Comparison of 0.05% cyclosporine and 3% Diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
    BMC Ophthalmology, 2019
    Co-Authors: Chang-hyun Park, Jongsuk Song, Kyung-chul Yoon, Tae Young Chung, Chul Young Choi
    Abstract:

    Background This study is aim to compare the clinical effectiveness between the two most prominent dry eye disease (DED)-specific eye drops, 0.05% cyclosporine (CN) and 3% Diquafosol (DQ). Methods This is a multi-centered, randomized, masked, prospective clinical study. A total of 153 DED patients were randomly allocated to use CN twice per day or DQ six times daily. Cornea and conjunctival staining scores (NEI scale), tear break-up time (TBUT), Schirmer test scores, and ocular surface disease index (OSDI) score were measured at baseline, 4 and 12 weeks after treatment. Results At 12 weeks after treatment, NEI scaled scores were significantly reduced from the baseline by − 6.60 for CN and − 6.63 for DQ group (all P  

  • Comparison of 0.05% cyclosporine and 3% Diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
    BMC Ophthalmology, 2019
    Co-Authors: Chang-hyun Park, Jongsuk Song, Kyung-chul Yoon
    Abstract:

    This study is aim to compare the clinical effectiveness between the two most prominent dry eye disease (DED)-specific eye drops, 0.05% cyclosporine (CN) and 3% Diquafosol (DQ). This is a multi-centered, randomized, masked, prospective clinical study. A total of 153 DED patients were randomly allocated to use CN twice per day or DQ six times daily. Cornea and conjunctival staining scores (NEI scale), tear break-up time (TBUT), Schirmer test scores, and ocular surface disease index (OSDI) score were measured at baseline, 4 and 12 weeks after treatment. At 12 weeks after treatment, NEI scaled scores were significantly reduced from the baseline by − 6.60 for CN and − 6.63 for DQ group (all P 

  • effect of Diquafosol tetrasodium 3 on the conjunctival surface and clinical findings after cataract surgery in patients with dry eye
    International Ophthalmology, 2018
    Co-Authors: Ying Li, Jee Myung Yang, Won San Choi, Kyung-chul Yoon
    Abstract:

    Purpose To investigate the effects of Diquafosol tetrasodium (DT) 3% on conjunctival impression cytologic findings in addition to clinical symptoms and signs after cataract surgery in patients with preexisting dry eye disease (DED).

Jun Shimazaki - One of the best experts on this subject based on the ideXlab platform.

  • long term safety and effectiveness of Diquafosol for the treatment of dry eye in a real world setting a prospective observational study
    Advances in Therapy, 2020
    Co-Authors: Yuichi Ohashi, Hitoshi Watanabe, Etsuko Takamura, Norihiko Yokoi, Jun Shimazaki, Masahiro Munesue, Akio Nomura, Fumiki Shimada
    Abstract:

    Diquafosol is a P2Y2 receptor agonist that has been shown to be effective in the treatment of dry eye disease (DED) in short-term studies; however, its long-term safety and effectiveness have not been evaluated in a real-world setting. This prospective, multicentre, open-label observational study was conducted in patients with DED over 12 months. Safety endpoints included the incidence of adverse drug reactions (ADRs) and serious ADRs. Effectiveness endpoints included change from baseline in keratoconjunctival staining score, tear film break-up time (BUT) and Dry Eye-related Quality of Life Score (DEQS). A total of 580 patients were included, most of whom were female (82.9%). The proportion of patients who completed 12 months of observation was 55.0%, the most common reason for discontinuation was patient decision (54.6%). The incidence of ADRs was 10.7% and was highest during the first month of treatment (5.5%); no serious ADRs were reported. Compared with baseline, significant improvements in all effectiveness outcomes, including keratoconjunctival fluorescein staining score, BUT and DEQS summary score, were observed at each evaluation during the treatment period (p < 0.001). The present, real-world study showed that Diquafosol 3.0% ophthalmic solution was well tolerated and effective in the long-term treatment of DED.

  • the effects of 3 Diquafosol sodium eye drops on tear function and the ocular surface of cu zn superoxide dismutase 1 sod1 knockout mice treated with antiglaucoma eye medications
    Diagnostics (Basel Switzerland), 2020
    Co-Authors: Yukari Yagiyaguchi, Kazuo Tsubota, Takashi Kojima, Murat Dogru, Osama M A Ibrahim, Kazunari Higa, Takahiko Shimizu, Jun Shimazaki
    Abstract:

    Anti-glaucoma eye drop treatment often induces dry eyes and can lead to poor medication adherence. This study aimed to investigate the effects of 3% Diquafosol sodium eye drops on tear function and the ocular surface epithelium in Sod1−/− mice after treatment with anti-glaucoma eye drops. The mice were divided into four groups: group 1, control group; group 2, anti-glaucoma eye drop; group 3, anti-glaucoma eye drops followed by a secretagogue eye drop (3% Diquafosol); and group 4, simultaneous anti-glaucoma and secretagogue eye drop. Mice underwent assessments of tear quantity, tear film breakup time, and vital staining score. Mice in groups 3 and 4 showed significantly better tear stability and lower corneal staining scores than mice in group 2 after eye drop instillations (p < 0.05). Mice in group 4 showed significantly better tear stability, lower corneal staining scores, and higher goblet cell densities than those in group 1 after eye drop instillations (p < 0.05). The conjunctival epithelium showed stratification and abundance of Muc5AC-positive goblet cells in group 4, whereas thinning with desquamation was observed with a few goblet cells in group 2. Thus, simultaneous administration of 3% Diquafosol sodium eye drops with topical anti-glaucoma drops showed favorable effects on tear stability and the corneal epithelium against the ocular surface toxicity inflicted by the anti-glaucoma eye drops.

  • The effects of 3% Diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2018
    Co-Authors: Keisuke Ikeda, Kazuo Tsubota, Takashi Kojima, Murat Dogru, Kazunari Higa, Takahiko Shimizu, Cem Simsek, Motoko Kawashima, Jun Shimazaki
    Abstract:

    Purpose The purpose of the study is to investigate the effect of 3% Diquafosol sodium eye drops on meibomian gland and ocular surface alterations in the superoxide dismutase-1 ( Sod1 ^ −/− ) mice in comparison to the wild-type mouse. Methods Three percent Diquafosol sodium eye drop was instilled to 20 eyes of 10 50-week-old male Sod1 ^ −/− mice and 22 eyes of 11 C57BL/6 strain 50-week-old wild-type (WT) male mice six times a day for 2 weeks. Aqueous tear secretion quantity was measured with phenol red-impregnated cotton threads without anesthesia. Tear film stability and corneal epithelial damage were assessed by fluorescein and lissamine green staining. We also performed oil red O (ORO) lipid staining to evaluate the lipid changes in the meibomian glands. Meibomian gland specimens underwent hematoxylin and eosin staining to examine histopathological changes and meibomian gland acinar unit density after sacrifice. Immunohistochemistry staining was performed using cytokeratin 4, cytokeratin 13, and transglutaminase-1 antibodies. Quantitative real-time polymerase chain reaction for cytokeratin 4, cytokeratin 13, and transglutaminase-1 mRNA expression was also performed. Results The aqueous tear quantity, the mean tear film breakup time, and the number of lipid droplets significantly improved in the Sod1 ^ −/− mice with treatment. The mean meibomian acinar unit density did not change in the Sod1 ^ −/− mice and WT mice after treatment. Application of 3% Diquafosol sodium eye drop significantly decreased the corneal fluorescein and lissamine green staining scores in the Sod1 ^ −/− mice after 2 weeks. We showed a notable increase in cytokeratin 4, cytokeratin 13 immunohistochemistry staining, and cytokeratin 4, cytokeratin 13 mRNA expressions with a marked decrease in immunohistochemistry staining and significant decline in mRNA expression of transglutaminase-1 after 3% Diquafosol sodium treatment. Conclusion Topical application of 3% Diquafosol sodium eye drop improved the number of lipid droplets, tear stability, and tear production which in turn appeared to have a favorable effect on the ocular surface epithelium. Three percent Diquafosol sodium eye drop may be a potential treatment for age-related meibomian gland and dry eye disease based on the observations of the current study.

  • real world assessment of Diquafosol in dry eye patients with risk factors such as contact lens meibomian gland dysfunction and conjunctivochalasis subgroup analysis from a prospective observational study
    Clinical Ophthalmology, 2015
    Co-Authors: Masahiko Yamaguchi, Hitoshi Watanabe, Etsuko Takamura, Norihiko Yokoi, Takeshi Nishijima, Jun Shimazaki, Yuichi Ohashi
    Abstract:

    Purpose To evaluate the efficacy and safety of Diquafosol (DQS) ophthalmic solution in dry eye (DE) patients wearing contact lenses (CLs) or with concomitant meibomian gland dysfunction (MGD) or conjunctivochalasis in a real-world setting.

  • clinical usefulness of Diquafosol for real world dry eye patients a prospective open label non interventional observational study
    Advances in Therapy, 2014
    Co-Authors: Masahiko Yamaguchi, Hitoshi Watanabe, Etsuko Takamura, Norihiko Yokoi, Takeshi Nishijima, Jun Shimazaki, Yuichi Ohashi
    Abstract:

    Introduction This study was designed to evaluate the efficacy and safety of 3% Diquafosol ophthalmic solution in dry eye patients in clinical practice.

Yuichi Ohashi - One of the best experts on this subject based on the ideXlab platform.